Introduction
While nonadhesive liquid embolic agents may have advantages over currently available adhesive agents, they present a variety of real and potential disadvantages, most of which center on the use of dimethyl sulfoxide (DMSO) as the solvent. Although the intravascular toxicity of DMSO could be controlled by slowing the injection rate in animal models, there remain safety concerns regarding its clinical use 1, 2 . We developed a mixture of ethylene vinyl alcohol copolymer (EVAL) and iopmaidol (Iopamiron; Nihon Schering, Osaka, Japan) dissolved in ethanol as an alternative solvent to offer a much safer means of embolizing arteriovenous malformation (AVM).
In an experimental study we investigated the properties, characteristics, and techniques of embolization using our new EVAL/Ethanol mixture 3 . We found it to be easy to handle, safe, and effective in a rabbit renal artery embolization model. Particularly attractive were its nonadhesive character and the fact that it allowed for repeated injections. Therefore, we posited that as an adjunct to neurosurgery, embolization with the EVAL/Ethanol mixture provide
Summary
We report our experience using our new nonadhesive liquid embolic agent, an ethylene vinyl alcohol copolymer (EVAL)/Ethanol mixture, to treat human arteriovenous malformations (AVM). Between June 1995 and April 2001, 57 patients with confirmed AVM underwent embolization with the EVAL/Ethanol mixture. Using 87 procedures consisting of one to three stages, we embolized 185 feeding arteries to occlude as much of the AVM as possible. Repeated injections under fluoroscopic control could be performed smoothly without encountering cementing of the catheter in the vessel wall.
Among 87 procedures undertaken in 57 patients, seven (8.0%) procedures in six patients produced new postembolization symptoms. Resolution of these symptoms occurred within hours or days following four of the seven procedures; permanent neurological deficits remained after three embolization procedures (3.4%) . Of the 57 patients, three underwent postembolization radiosurgery, 54 were radically treated with microsurgical extirpation.
Histopathological examinations of the 54 specimens disclosed mild inflammation within the embolized lumen without inflammatory reactions in the media or adventitia. Follow-up angiograms obtained three years after they underwent radiosurgery showed that in all three patients the nidus had completely disappeared.
reduced flow and occlusion to deep feeding arteries. We now report our initial clinical experience with EVAL/Ethanol embolization. The study protocol was approved by the local ethical committee and informed consent was obtained from all patients or their closest relatives before inception of the study.
Subjects and Methods

Patients
Between June 1995 to April 2001, 57 patients with confirmed AVMs underwent EVAL/Ethanol embolization at Kumamoto University Hospital. Of these, 45 presented with haemorrhage from their AVM, six with at least one seizure episode, and two each with headache or visual field deficits; two patients were diagnosed incidentally. The patients (32 males, 25 females) ranged in age from eight to 63 years (mean age, 32.7 years). According to the Spetzler-Martin grading system, 2 lesions were of grade I, 16 of grade II, 27 of grade III, and 12 of grade IV. Of the 57 lesions, 33 (57.9%) were located in the eloquent area of the brain. Using 87 one-tothree stage procedures, 185 feeding arteries were embolized to occlude as much of the AVM nidus as possible. Subsequent embolizations were performed after an interval of approximately one to two weeks. Postembolization, 54 patients were treated with radical microsurgical extirpation, the other three underwent radiosurgical intervention because they refused surgical excision.
Procedures
All procedures were performed in the interventional neuroangiography suite using highresolution digital subtraction angiography and the road-mapping technique. Embolization was performed with the patient under local anesthesia using the transfemoral approach; all were awake throughout the procedure with the exception of five children younger than 12 years, they were placed under general anesthesia. A 6F sheath was placed into the femoral artery and a 6F guiding catheter was inserted through the sheath. Systemic anticoagulation was achieved during the procedures with heparin 3000 U bolus followed by 1000 U of heparin ever hour. Most embolizations were performed with a Tracker-18 catheter (Target Therapeutics, Fremont, CA). The tip of the mi-crocatheter was gently guided into the proper artery and carefully positioned as close as possible to the nidus. After superselective angiography, an appropriate dose of amobarbital (Amytal sodium; Eli Lilly and Co., Indianapolis, IN) was injected (usually 30-50 mg) to evaluate the patient for potential neurological deficits and immediate examination was performed to detect neurological deficits related to this injection. In the 5 pediatric patients under general anesthesia, the provocative testing was not performed. After confirming a negative amobarbital test, 0.6 ml of 30% ethanol (slightly in excess of the amount needed to fill the 0.53 ml Tracker-18 catheter) was injected to irrigate the catheter lumen. This was followed by injection via a tuberculin syringe of the EVAL/Ethanol mixture and repeated until complete obliteration was confirmed under direct fluoroscopic viewing. Since the material is not adhesive and of low viscosity, multiple injections could be administered. To assess the progress of the embolization, we performed angiography via the guiding catheter during a pause in the injection. At the end of the procedure, the catheter was withdrawn slowly and a final angiogram was obtained to check the occlusion of the embolized artery. Depending on the size of the AVM, one or two more injections were performed into different feeders. All catheters used during the procedure, including the guiding catheters and the microcatheters, were continuously flushed with heparinized saline (5000 U/L) via an infusion pump.
Vital signs and neurologic function were monitored during and after the procedure. The patients were subsequently moved to the intensive care unit for further observation. On the 1st postoperative day, all patients underwent computerized tomography (CT) scans for evaluation of edema, mass effect, infarct, or haemorrhage. The interval between the last embolization and surgery was approximately 1 to 2 weeks. Surgical specimens, fixed in 10% neutral buffered formalin and routinely processed for light microscopy, were sectioned at 3 µm and stained with both hematoxylin-eosin and elastica van Gieson.
Results
A total of 87 procedures were performed; 32 patients underwent one procedure, 20 patients required two, and five patients required three serial procedures. Typical injection volumes were between 0.7 and 0.9 ml and the average injection time was two to three min. Average volumes and injection times increased as we acquired more experience with the technique. The embolization material was of low viscosity and easily passed through the narrow lumen of the microcatheter, even the Tracker-10 catheter. Repeated injections under fluoroscopic control went smoothly, we encountered no cementing of the catheter in the vessel in any of the procedures. Complete vessel occlusion was confirmed Figure 1 This is illustrative of patients who underwent embolization followed by surgery. This 23-year-old man with a history of medically controlled seizures presented with severe headache. CT scan revealed an intracerebral haemorrhage in the left parietal lobe. Feeders were derived from middle cerebral artery (MCA); venous drainage was superficial. A) Lateral view of the left internal carotid artery (ICA) demonstrates these findings. He underwent two-stage embolization. A large branch arising from the inferior trunk of MCA and leading to the arteriovenous malformation (AVM) was catheterized first. B) This superselective angiogram shows a lateral view of the tip of the microcatheter and the filled part of the nidus. C) Further EVAL/Ethanol infusion, without removal of the microcatheter, to evaluate nidus obliteration and additional delivery of the mixture through the same microcatheter. D) The feeding artery arising from the inferior trunk of MCA is seen to be completely embolized. Eventually, a total of four separate feeders were embolized. E) At the conclusion of the embolization procedures, there is a significant reduction in flow through the nidus. Surgical resection was performed one month after the first embolization. The postoperative angiogram showed complete resection of the AVM. angiographically immediately after the embolization procedure (figure 1). No patients experienced ethanol toxicity. We did not encounter occlusion of any of the draining vessels during the embolization procedure, however, in 4 large feeding vessels we noted partial occlusion of the draining venous outlet. None of our patients experienced peri-or postembolization intracranial haemorrhage from normal pressure breakthrough or venous outlet obstruction.
In six patients undergoing a total of seven embolization procedures (8.0%) we noted new clinical symptoms after embolization; CT scans detected ischemic changes that correlated with these symptoms. They were motor weakness (four patients), new visual field deficits (two patients), comprehension or memory disturbance (two patients); two of the six patients presented with two symptoms. In four of these seven procedures, symptom resolution occurred within hours or a few days after onset. Of the 87 procedures, three (3.4%) resulted in new permanent neurological deficits. Postembolization CT scans revealed new abnormalities following three embolization procedures performed on three patients; however, all of these patients remained asymptomatic.
Of the 57 patients all but three who declined surgical treatment underwent surgical excision of their AVM; three patients were treated with radiosurgery. At surgery, the color of the embolized feeding vessel and the nidus was observed to have changed to white, partially mixed with dark brown. They were soft enough to allow retraction from surrounding normal tissues; coagulation and sectioning with microscissors were easily achieved. Of the 57 patients who underwent embolization, three were treated with radiosurgery. The AVM in these patients measured approximately 40 mm on the initial angiograms. After embolization, the residual nidus was less than 25 mm and at three year follow-up, angiograms confirmed its complete disappearance (figure 2). Only further prolonged follow-up will determine the degree of permanence of this treatment.
All 54 surgical specimens were histopathologic analyzed. The light gray EVAL sponges were found to be in direct contact with the entire circumference of the endothelial surface and old haemolyzed red blood cells were entrapped within the sponges. In patients who underwent excision within two weeks of embolization we noted varying degrees of inflammation manifested by the presence of a few lymphocytes and neutrophilic granulocytes within the embolized lumens. Although there was complete endothelial denuding and intimal damage, the internal elastic lamina was only focally disrupted; there were scarcely inflammatory infiltrates in the media and adventitia. In patients who underwent excision more than two weeks after embolization, these histopathologic changes were slightly more pronounced, however, there was no evidence of intramural haemorrhage or extravasation of the embolization materal ( figure 3 ).
Discussion
Comparison of the EVAL/Ethanol Mixture with Other Embolic Agents
Many embolic agents have been used in the treatment of brain AVM. The most widely used embolic materials consist of varying sizes of polyvinyl alcohol (PVA) derivative and microcoils, of silk sutures, absolute ethyl alcohol, and various tissue adhesives [4] [5] [6] [7] [8] [9] . PVA does not provide permanent occlusion and the choice of particles that are too small may result in fatal pulmonary insufficiency because the particles are radiolucent. Coils produce very proximal occlusion, they do not occlude at the nidus, and they are not easily resectable. While silk sutures are inexpensive and readily available, they can induce an intense inflammatory response, they are difficult to see, and their ultimate location is frequently unknown. Ethanol is also inexpensive and easy to deliver and while it appears to be very effective in occluding blood vessel, safety concerns limit its use.
Among liquid embolic agents, n-butylcyanoacrylate (NBCA: Cordis Neurovascular Inc., Miami, FL) is now the most extensively used. The intranidal infusion of NBCA is successful in some cerebral AVM, and it has recently received U.S. Food and Drug Administration approval for the treatment of cerebral AVMs. However, there are some risks and complications relatively specific to embolization with cyanoacrylate adhesives. Cyanoacrylate is almost immediately polymerized upon contact with the vascular endothelium and ionic fluids such as blood. Therefore, modification of the polymerization process is required to allow for safe delivery through a microcatheter 10 . If the polymerization time is too long, the material will migrate the nidus and be polymerized within the venous drainage of the AVM, resulting in venous occlusion and consequent venous infraction or intranidal haemorrhage. If polymerization occurs too rapid, the arterial feeding pedicle is occluded before the nidus, allowing nidal revascularization and the development of a collateral supply. Suh et Al 11 , reported that the degree of premature polymerization was different for different lots of Lipiodol and different NBCA concentrations. Therefore, significant precautions must be taken to achieve appropriate polymerization times. NBCA is an excellent embolization agent in cases where the microcatheter can be placed inside the nidus, however, the positioning of the microcatheter into the nidus can be difficult, prolonging the procedure time and increasing the risk of stroke. Embolization with tissue adhesives entails the risk of permanently gluing the catheter tip within the cerebral vessel, therefore, the successful use of this agent depends critically on the skill and experience of the operator. Furthermore, surgical excision after the use of tissue adhesives can be complicated; although these agents are now highly diluted with Ethiodol, surgical retraction, cutting, and coagulation can be somewhat difficult. Figure 2 This is illustrative of the three patients who underwent embolization followed by radiosurgery. This 32-year-old woman was found to have a left temporal AVM during evaluation for a single seizure episode. She was neurologically intact and had no history of haemorrhage. Feeders were derived from the left MCA. Venous drainage was via superficial cortical veins. A) Lateral view of the left ICA demonstrates these findings. The two feeding arteries derived from the MCA were embolized uneventfully, however, the nidus remained. B) This superselective angiogram shows a lateral view of the tip of the microcatheter and the filled part of the nidus. C) The flow through the AVM was substantially reduced and the remaining nidus measured less than 25 mm. She underwent radiosurgery two weeks after the embolization. D) The follow-up angiogram obtained 38 months later shows complete disappearance of the AVM. Throughout the treatment period, this patient remained asymptomatic.
A C D B
In the 1990's Taki et Al 12 , developed the original formulation of Onyx (Onyx Liquid Embolic System; Micro Therapeutics, Inc., Irvine, CA). It was used extensively in Japan to treat cerebral AVM and for tumor embolization. More recently, Onyx has been used in Europe, and it is currently being investigated as an embolic material in the United States for treatment of both cerebral AVMs and large and giant intracranial aneurysms 13, 14 . Onyx is a liquid, opaque embolic material that is easily injected through a microcatheter; its nonadhesive nature allows for more controlled and longer delivery without catheter gluing. In addition, it is supplied in premixed vials, and no preparation is required before injection.
However, its use of dimethyl sulfoxide (DM-SO) as the solvent is a distinct disadvantage. If given at too high a volume or concentration, DMSO is toxic to blood vessels and may lead to acute vessel damage, necrosis, or vasospasm; therefore, only small amounts of DMSO can be injected directly into cerebral blood vessels over certain time periods. Thus, the therapeutic window is at best relatively narrow and safety concerns regarding the use of DMSO remain. In addition, the use of DMSO as a solvent requires an appropriate, compatible delivery system because DMSO dissolves the plastics used in the manufacture of many of the commercially available microcatheters.
Mindful of the attractive properties of EVAL, we developed an EVAL/Ethanol mixture that uses ethanol as the alternative solvent. In the clinical setting, we found it handled easily, and its delivery through the microcatheter could be achieved smoothly because of its low viscosity. Since the mixture is completely nonadhesive, multiple injections can be performed using the same microcatheter, without the danger of its becoming cemented into place. Microcatheter withdrawal after embolization was smooth in all 87 procedures. In high-flow AVM, the EVAL/Ethanol mixture was less than optimally radiopaque at the beginning of embolization, however, the degree of nidus occlusion and the status of the draining veins could be checked via repeat angiograms.
The possibility of obtaining angiograms during the injection of the medium provided a considerable advantage because it allowed us to monitor the degree of the nidus obliteration and to check the state of the pertinent draining veins. Furthermore, the mixture was easily identified fluoroscopically during slowing of the vascular flow.
Permanence
Permanence is an important issue regarding embolic agents used to occlude AVM, particularly when embolization is performed in conjunction with radiosurgery. Yakes et Al 9 , reported a series of 17 AVM embolized with absolute ethanol. They achieved angiographic cure in 41% of their patients; the mean follow-up period was 13 months. Although recanalization of the nidus after embolization with ethanol appears to be rare, NBCA embolization resulting in dense casting of the nidus is thought to have a higher angiographic cure rate than embolization using other available embolic agents. Our experimental study 3 was not designed to assess the permanence of EVAL/Ethanol embolization; the rabbit kidneys were evaluated pathologically 4 months after embolization. We are not aware of any reports that EVAL is carcinogenic in humans and the mutagenicity of EVAL is unknown.
For these reasons, we used the mixture only as a preoperative adjunct. All three patients who underwent radiosurgery because they refused surgical excision demonstrated angiographic cure; the mean follow-up period in this group was 35 months. However, larger patient populations and longer follow-up periods must be considered before it is possible to draw any conclusions regarding the degree of permanence of our EVAL/Ethanol mixture.
Complications
The most common significant complications resulting from embolization were cerebral infarction identified on CT scans. Of 87 procedures, seven (8.0%) resulted in new clinical symptoms, three (3.4%) in permanent neurological deficits and four (4.6%) produced transient symptoms that resolved over the course of hours or a few days postembolization. In all patients with permanent neurological deficits or transient symptoms, new areas of hypodensity due to inadvertent occlusion of normal arteries were observed on CT scans; these correlated with the symptoms. Other series have reported endovascular complication rates between 3 and 25% [15] [16] [17] [18] [19] [20] . The complications we en-countered were not different in nature or frequently from those that are generally faced in the performance of cerebral embolization, irrespective of the embolic material used.
We encountered no occlusion of draining venous outlets during embolization, however, partial venous outlet obstructions were produced in 4 large feeding vessels. As this complication appears relatively specific to embolization with our mixture, it may not be suited for use in some lesions such as single arteriovenous fistula or AVM that contains a large arteriovenous fistula. For application in these cases, a mixture with more easily controllable polymerizing time is necessary.
The benefits of AVM embolization must be weighted against the risk of producing serious complications. Continued improvements in embolization techniques and devices will surely enhance the therapeutic success rate and decrease the complication rates. For the optimally safe and effective treatment of specific vascular lesions, the first step consists of clearly identify-ing the lesion by means of imaging or physical examination and of defining the goal of embolization. When embolization is used as an adjunct to surgery, its goal is to enhance the safety of surgery, usually by reducing the flow to the AVM and by occluding deep feeding arteries, which can be difficult to control at the time of excision.
Histopathology of the Surgical Specimens
Histopathologically, most of the surgical specimens were similar to the subacute specimens described in our experimental study 3 . Our findings differed from those of Fukushima et Al 21 , who reported that after 4 weeks, cerebral AVM embolized with an EVAL/DMSO mixture exhibited extensive endoluminal and intramural inflammatory infiltrates and perivascular haemorrhage. Considering the duration between embolization and excision, our surgical specimens showed less inflammatory reaction in the vessel wall than did specimens embolized with an EVAL/DMSO mixture. Jahan et Al 13 , used Onyx to treat 23 patients with cerebral AVMs; in 2 of 11 patients who had undergone resection one day after embolization, histopathological examination of resected AVM revealed angionecrosis involving many vessels. This suggests that exposure of the microvasculature to DMSO may play a major role in the histopathologic response to this material. Our experimental study 3 revealed that EVAL was not extravasated and there were no intramural haemorrhage in the renal vessels embolized with the EVAL/Ethanol mixture. At present we cannot explain this difference between our and other embolization materials, however, our findings support our contention that the EVAL/Ethanol mixture may be a highly desirable embolic agent for the preoperative embolization of cerebral AVM.
Conclusions
The EVAL/Ethanol mixture was easy to handle and appear to be an effective and safe embolic agent for the preoperative embolization of cerebral AVMs. Our preliminary study points to the feasibility of using this agent in the clinical setting. However, as its safety and superiority over currently available embolic agents can only be demonstrated after further long-term studies, its use should be limited to patients already scheduled for surgical excision.
